Vaxcyte, Inc. Stock Price, News & Analysis

Vaxcyte (Nasdaq: PCVX) announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022. The presentation is set for 2:20 p.m. ET / 11:20 a.m. PT. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on engineering high-fidelity vaccines to combat bacterial diseases, with its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) has announced a public offering of 2,500,000 shares of common stock and pre-funded warrants, priced at $20.00 and $19.999 per share, respectively. The offering is expected to generate approximately $100 million in gross proceeds, excluding the exercise of warrants. The offering is anticipated to close on January 18, 2022, subject to customary conditions. Vaxcyte has also granted underwriters a 30-day option for an additional 750,000 shares.

Vaxcyte, Inc. (Nasdaq: PCVX) announced a public offering of common stock and pre-funded warrants, with underwriters having a 30-day option to purchase an additional 15% of shares. The offering's terms are subject to market conditions and lack definitive timelines. Leading the offering are BofA Securities, Jefferies, and Evercore ISI. A shelf registration statement has been effective since July 2, 2021. The company's focus is on developing advanced vaccines, including its lead candidate, VAX-24, targeting invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) announced the FDA's clearance of the Investigational New Drug application for VAX-24, its 24-valent pneumococcal conjugate vaccine. This marks a pivotal step as Vaxcyte transitions to a clinical-stage company. The Phase 1/2 clinical study is set to initiate in Q1 2022, with topline results expected by the end of the year. VAX-24 aims to address the significant public health challenge of pneumococcal disease, which affects hundreds of thousands annually in the U.S. The company is also advancing VAX-XP, designed to cover over 30 strains.

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine developer, will participate in several virtual investor conferences aimed at enhancing global health through innovative vaccine solutions. Key events include the Jefferies London Healthcare Conference from November 16-19, 2021, the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29-December 2, 2021, and the Evercore ISI 4th Annual HealthCONx Virtual Conference from November 30-December 2, 2021. Webcasts of these discussions will be available on Vaxcyte’s website for about 30 days.

Vaxcyte, Inc. (Nasdaq: PCVX) reported its Q3 2021 financials and business updates, announcing the completion of the GMP drug product manufacturing and GLP toxicology study for its VAX-24 vaccine. The company anticipates submitting the VAX-24 IND application to the FDA in Q1 2022. Q3 net loss was $26.6 million, compared to $21.0 million in Q3 2020. R&D expenses rose to $20.4 million from $16.4 million, attributed to personnel and project-related costs. Cash reserves as of September 30, 2021, were $318.3 million, down from $386.2 million at year-end 2020.

Vaxcyte, Inc. (Nasdaq: PCVX) announced the appointment of Carlos Paya as Board Chair and Michael Kamarck to its board of directors. Both leaders bring extensive experience in biopharmaceuticals and vaccine development. CEO Grant Pickering emphasized their expertise will help advance Vaxcyte’s mission to create next-generation vaccines, including the VAX-24 pneumococcal vaccine. The company aims to improve global health by developing superior vaccines targeting infectious diseases.

Vaxcyte, Inc. (Nasdaq: PCVX) announced participation in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5, 2021, at 11:30 am ET. A live webcast will be available through the Company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on developing novel vaccines to combat infectious diseases, featuring advanced technologies like the XpressCF™ platform. Their lead candidate, VAX-24, targets invasive pneumococcal disease.

On September 21, 2021, Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 2021 Cantor Virtual Global Healthcare Conference. This event will take place on September 28, 2021, at 8:40 AM ET. A live webcast will be available on the company's website, with a replay accessible for 30 days post-conference. Vaxcyte is focused on developing advanced vaccines against common infectious diseases, with its lead candidate, VAX-24, targeting invasive pneumococcal disease.